In a strategic reshuffle following the exit of its product chief, Netflix has merged its product and technology divisions under veteran executive Elizabeth Stone, signaling a tighter integration of engineering and user experience.
While many AI stocks soared in 2025, Salesforce shares faced significant headwinds. Despite a challenging year, the cloud software giant's robust fundamentals and reasonable valuation suggest it may be poised for a recovery.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A discounted cash flow valuation of GrainCorp Limited suggests its current share price may not fully reflect its future cash generation potential, indicating a possible opportunity for investors.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
Bank of America's stock has retreated roughly 5% over the past month, trading below key fair value estimates. Analysts are divided on whether this presents a value entry point or reflects growing market apprehension about interest margins and credit quality.
As inflation persists, Baby Boomers are leveraging decades of financial experience to cut costs strategically. We examine the key spending categories they avoid and the generational mindset behind their money choices.
As global leaders gather in Davos, a coalition of over 400 affluent individuals from 24 nations issues a stark demand: governments must impose higher taxes on the ultra-wealthy to tackle inequality.
A new study reveals the cost gap between Waymo's driverless vehicles and human-driven Uber and Lyft rides is shrinking, signaling a pivotal moment for the competitive robotaxi industry.
A broad sell-off in risk assets, from equities to precious metals, has triggered over $2.5 billion in Bitcoin liquidations. Analysts point to shifting Federal Reserve expectations and AI trade anxieties as key drivers behind the latest crypto market tremor.
CNBC's Jim Cramer lauds Salesforce's operational strength, yet the stock, alongside peer ServiceNow, faces persistent 'multiple compression' as Wall Street reevaluates growth expectations for mature software leaders.
CNBC's Jim Cramer spotlighted Royal Caribbean Cruises Ltd. (RCL) this week, praising its ambitious full-year 2026 forecast as the cruise line capitalizes on robust post-pandemic demand and operational efficiencies.
CNBC's Jim Cramer concedes he misjudged the explosive demand for Apple's iPhone 17, which powered the tech giant to a staggering earnings beat that caught Wall Street off guard.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Despite modest nominal gains, real wages for U.S. workers are failing to keep pace with the cost of living, with a majority reporting financial strain as structural economic shifts and technological efficiencies redirect gains away from paychecks.
Amazon's latest round of layoffs will eliminate over 2,200 corporate positions in the Seattle region, part of a broader 16,000-person global workforce reduction. The cuts, effective from late April, add to a wave of job losses hitting Washington's tech sector.
Despite its dominance and a recent surge to over 325 million subscribers, Netflix faces mounting criticism over pricing, content decisions, and user experience. An analysis of consumer feedback reveals the key frustrations testing viewer loyalty in an increasingly competitive streaming landscape.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
